Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6931 to 6945 of 7690 results

  1. Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

    Discontinued [GID-TA10375]

    Technology appraisal guidance
    Discontinued

  2. PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502

    Discontinued [GID-TA10402]

    Technology appraisal guidance
    Discontinued

  3. Pelareorep for untreated pancreatic cancer [ID1074]

    Discontinued [GID-TA10689]

    Technology appraisal guidance
    Discontinued

  4. Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940

    Discontinued [GID-TA10397]

    Technology appraisal guidance
    Discontinued

  5. Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]

    Discontinued [GID-TA10686]

    Technology appraisal guidance
    Discontinued

  6. Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]

    Discontinued [GID-TA10687]

    Technology appraisal guidance
    Discontinued

  7. Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

    Discontinued [GID-TA10447]

    Technology appraisal guidance
    Discontinued

  8. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]

    Discontinued [GID-TA10144]

    Technology appraisal guidance
    Discontinued

  9. Pelareorep for treating recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer [ID1099]

    Discontinued [GID-TA10688]

    Technology appraisal guidance
    Discontinued

  10. Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]

    Discontinued [GID-TA10709]

    Technology appraisal guidance
    Discontinued

  11. AT406 for neoadjuvant treatment of epithelial ovarian cancer [ID1428]

    Discontinued [GID-TA10809]

    Technology appraisal guidance
    Discontinued

  12. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]

    Discontinued [GID-TA10569]

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab for previously treated endometrial cancer [ID1205]

    Discontinued [GID-TA10243]

    Technology appraisal guidance
    Discontinued

  14. Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]

    In development [GID-TA10851] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]

    In development [GID-TA10906] Expected publication date: TBC

    Technology appraisal guidance
    In development